Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Hospira UK Ltd, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
Cytarabine 20 mg/ml Injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless solution. |
Each 1 ml contains 20 mg of cytarabine.
| Presentations | 100 mg/5 ml | 500 mg/25 ml | 1 g/50 ml |
| Amount cytarabine present | 100 mg | 500 mg | 1 g |
Excipient with known effect:
Cytarabine 100 mg/5 ml (20 mg/ml) Injection contains 13.25 mg of sodium in each vial.
Cytarabine 500 mg/25 ml (20 mg/ml) Injection contains 66.75 mg of sodium in each vial.
Cytarabine 1 g/50 ml (20 mg/ml) Injection contains 133.5 mg of sodium in each vial.
For the full list of excipients see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cytarabine |
Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes. |
| List of Excipients |
|---|
|
Sodium chloride |
Clear Type I glass vials, rubber stopper.
Clear Type I Onco-Tain Vials, rubber stopper.
Pack sizes 5’s, 25’s and 50’s.
Not all presentations and pack sizes may be marketed.
Hospira UK Ltd, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
PL 04515/0040
Date of first authorisation: 7th July 1992
Date of last renewal: 10th October 2006
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
